A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
NCT06603246
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-cystic Fibrosis Bronchiectasis
- Chronic Obstructive Pulmonary Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Genentech, Inc.
- Last updated on ClinicalTrials.gov
- September 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
California · 1
- Stanford Center for Excellence in Pulmonary Biology · Palo Alto, CA
Kansas · 1
- University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd · Kansas City, KS
North Carolina · 1
- University of North Carolina Clinical Research Center · Chapel Hill, NC
Pennsylvania · 1
- UPMC Montefiore Hospital · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.